Mitsui & Co., Ltd. ("Mitsui", Head Office: Tokyo, President and CEO: Kenichi Hori) has entered a service agreement with Oncoshot Pte. Ltd. ("Oncoshot") on the utilization of Oncoshot's proprietary clinical data analysis technology. Oncoshot is a participant in the MSK iHub, a business accelerator program promoting digital healthcare innovation through industry collaborations with Memorial Sloan Kettering Cancer Center ("MSK"), a leading global cancer center.

Through its collaboration with MSK iHub and other related projects, Oncoshot and Mitsui aim to draw on real-world data (RWD)^* to advance the standardization of oncology clinical data, promote international collaborative research, shorten clinical study timelines, and generate evidence based on diverse patient populations. Participants will include oncology specialists practicing within the IHH Healthcare Berhad ("IHH") network, a leading international healthcare provider whose largest shareholder is Mitsui, as well as other oncology specialists in the Asia-Pacific region.

Demand for clinical data is rising across clinical research, drug discovery, and trial design. However, much of this valuable data remains fragmented and unstructured within individual healthcare institutions, while privacy regulations and institution-specific data governance requirements can restrict how data is transferred and used. As a result, access to high-quality clinical data, particularly from Asian patient populations, remains limited, reflecting not only challenges in data quality but also the lack of secure, sustainable, and practical mechanisms for data access.

Oncoshot has developed an AI-powered technology that efficiently anonymizes and structures data within healthcare institutions, including electronic medical records and laboratory analysis results, and converts it into research-and drug development-ready datasets without having to move the data out of the institution. This technology has the potential to accelerate the utilization of clinical data while abiding by strict privacy, access and governance constraints.

Through this initiative, Mitsui aims to enhance IHH's corporate value by further advancing the sophistication of its healthcare services, while also contributing to greater efficiency and effectiveness in the clinical development of pharmaceuticals through the utilization of clinical data.

Under its Medium-term Management Plan 2029, Mitsui has identified "Wellness Ecosystem Creation 2.0" as one of its Key Strategic Initiatives. In line with this strategy, Mitsui is working to expand access to advanced healthcare through IHH and to contribute to pharmaceutical innovation through the utilization of clinical data.

By utilizing Oncoshot's advanced clinical data platform, Mitsui aims to create an environment in which healthcare professionals across the IHH network can more readily access opportunities for knowledge exchange with leading international research institutions and participate in clinical research activities. Through these efforts, Mitsui seeks to support the continued development of medical expertise, expand access to innovative treatment opportunities for patients, and contribute to improving the quality of cancer care across the Asia-Pacific region.

Yoichiro Endo, Chief Operating Officer, Wellness Business Unit, Mitsui, said,
"As progress in pharmaceuticals and other medical technologies continues to drive greater personalization and complexity in healthcare, we are excited by the opportunity to contribute to the advancement of global healthcare by maximizing the value of RWD accumulated in clinical settings, including within IHH, together with technologies such as AI. Through the effective use of data, we aim not only to improve standards of care, but also to accelerate and enhance the efficiency of new drug development.

Building on this initiative, Mitsui aims to expand data collaboration among IHH, our affiliated company, and leading medical institutions in Japan and across the Asia-Pacific region. By leveraging these assets and partnerships, we also intend to develop new business opportunities in the United States and other markets at the forefront of pharmaceutical innovation and new drug development. Through these efforts, Mitsui will further strengthen its support for IHH, a leading advanced healthcare platform, while enabling it to play an even greater role in advancing pharmaceutical innovation. We are committed to providing even stronger support for IHH as it expands its significance and role."

Dr. Peter Chow, CEO, IHH Healthcare Singapore, said,
"IHH Healthcare welcomes this partnership as an important step in advancing complex cancer care across our network. By connecting our specialists with world-leading cancer care institutions such as MSK through this initiative, we will deepen knowledge exchange and strengthen oncology research through the use of clinical data and technologies including AI. Together, and with our relationship with Mitsui, these efforts will enhance clinical excellence and support better outcomes for cancer patients."

Neil J. Shah, MBBS, Assistant Attending Physician, MSK, said,
"MSK is excited to partner with Oncoshot and its network of affiliated hospitals across the Asia-Pacific region. Cancer is a global disease, and advancing care requires a deeper understanding of treatment outcomes across diverse patient populations and healthcare systems. At MSK, we have developed a standardized pan-cancer data model—the Common Cancer Data Elements (CCDE)—which provides an ontology-driven framework for harmonizing and analyzing oncology outcomes data. This collaboration will help us integrate data across countries, support global oncology research, and generate insights to improve cancer care worldwide."

* Real-world data (RWD): Medical data that is accumulated on a daily basis in actual clinical settings. While clinical trial data is used to demonstrate the efficacy of pharmaceutical products, real-world data is used to understand actual treatment practices and outcomes in real-world settings. In recent years, it has attracted increasing attention as an important foundation supporting drug discovery, the improvement of clinical trial efficiency, and other healthcare initiatives.

Company Profile

Collaboration framework of this initiative

Mount Elizabeth Novena Hospital, one of the hospitals within the IHH Network (Singapore)